These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 22536975)

  • 1. Fine-tuning anti-tumor immunotherapies via stochastic simulations.
    Caravagna G; Barbuti R; d'Onofrio A
    BMC Bioinformatics; 2012 Mar; 13 Suppl 4(Suppl 4):S8. PubMed ID: 22536975
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tumour suppression by immune system through stochastic oscillations.
    Caravagna G; d'Onofrio A; Milazzo P; Barbuti R
    J Theor Biol; 2010 Aug; 265(3):336-45. PubMed ID: 20580640
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Distributed delays in a hybrid model of tumor-immune system interplay.
    Caravagna G; Graudenzi A; d'Onofrio A
    Math Biosci Eng; 2013 Feb; 10(1):37-57. PubMed ID: 23311361
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The four-dimensional Kirschner-Panetta type cancer model: How to obtain tumor eradication?
    Krishchenko AP; Starkov KE
    Math Biosci Eng; 2018 Oct; 15(5):1243-1254. PubMed ID: 30380309
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mechanisms and applications of interleukins in cancer immunotherapy.
    Anestakis D; Petanidis S; Kalyvas S; Nday CM; Tsave O; Kioseoglou E; Salifoglou A
    Int J Mol Sci; 2015 Jan; 16(1):1691-710. PubMed ID: 25590298
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cancer immunotherapies, their safety and toxicity.
    Alatrash G; Jakher H; Stafford PD; Mittendorf EA
    Expert Opin Drug Saf; 2013 Sep; 12(5):631-45. PubMed ID: 23668362
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Determination of the optimal therapeutic protocols in cancer immunotherapy.
    Cappuccio A; Castiglione F; Piccoli B
    Math Biosci; 2007 Sep; 209(1):1-13. PubMed ID: 17416392
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Global sensitivity analysis and model-based reactive scheduling of targeted cancer immunotherapy.
    Kiran KL; Lakshminarayanan S
    Biosystems; 2010 Aug; 101(2):117-26. PubMed ID: 20639123
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Delivering safer immunotherapies for cancer.
    Milling L; Zhang Y; Irvine DJ
    Adv Drug Deliv Rev; 2017 May; 114():79-101. PubMed ID: 28545888
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Size-independent differences between the mean of discrete stochastic systems and the corresponding continuous deterministic systems.
    Gadgil CJ
    Bull Math Biol; 2009 Oct; 71(7):1599-611. PubMed ID: 19322613
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intratumoral immunotherapy: using the tumor as the remedy.
    Marabelle A; Tselikas L; de Baere T; Houot R
    Ann Oncol; 2017 Dec; 28(suppl_12):xii33-xii43. PubMed ID: 29253115
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mechanisms and therapeutic potentials of cancer immunotherapy in combination with radiotherapy and/or chemotherapy.
    Yu WD; Sun G; Li J; Xu J; Wang X
    Cancer Lett; 2019 Jun; 452():66-70. PubMed ID: 30902563
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The role of antigen-specific and non-specific immunotherapy in the treatment of cancer.
    Monjazeb AM; Hsiao HH; Sckisel GD; Murphy WJ
    J Immunotoxicol; 2012; 9(3):248-58. PubMed ID: 22734880
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Innate Immune Cells and Their Contribution to T-Cell-Based Immunotherapy.
    Ginefra P; Lorusso G; Vannini N
    Int J Mol Sci; 2020 Jun; 21(12):. PubMed ID: 32580431
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Current and Future Applications of Novel Immunotherapies in Urological Oncology: A Critical Review of the Literature.
    Özdemir BC; Siefker-Radtke AO; Campbell MT; Subudhi SK
    Eur Urol Focus; 2018 Apr; 4(3):442-454. PubMed ID: 29056275
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunotherapy: enhancing the efficacy of this promising therapeutic in multiple cancers.
    Inthagard J; Edwards J; Roseweir AK
    Clin Sci (Lond); 2019 Jan; 133(2):181-193. PubMed ID: 30659159
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prospects for personalized combination immunotherapy for solid tumors based on adoptive cell therapies and immune checkpoint blockade therapies.
    Kato D; Yaguchi T; Iwata T; Morii K; Nakagawa T; Nishimura R; Kawakami Y
    Nihon Rinsho Meneki Gakkai Kaishi; 2017; 40(1):68-77. PubMed ID: 28539557
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Metronomic chemotherapy and immunotherapy in cancer treatment.
    Chen YL; Chang MC; Cheng WF
    Cancer Lett; 2017 Aug; 400():282-292. PubMed ID: 28189534
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pure multiplicative stochastic resonance of a theoretical anti-tumor model with seasonal modulability.
    Zhong WR; Shao YZ; He ZH
    Phys Rev E Stat Nonlin Soft Matter Phys; 2006 Jun; 73(6 Pt 1):060902. PubMed ID: 16906802
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Optimization of interleukin-21 immunotherapeutic strategies.
    Cappuccio A; Elishmereni M; Agur Z
    J Theor Biol; 2007 Sep; 248(2):259-66. PubMed ID: 17574601
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.